{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:02:56Z","timestamp":1784257376924,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bulcan.2018.06.011","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T00:03:16Z","timestamp":1538179396000},"page":"1052-1073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["La morphine dans le cadre du changement d\u2019opio\u00efdes ou de voie d\u2019administration, chez l\u2019adulte avec une douleur due au cancer"],"prefix":"10.1016","volume":"105","author":[{"given":"Nathalie","family":"Michenot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rostaing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Jovenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Hubault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maril\u00e8ne","family":"Filbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gis\u00e8le","family":"Chvetzoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Minello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Magnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2341-7744","authenticated-orcid":false,"given":"Didier","family":"Ammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Krakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2018.06.011_bib0220","series-title":"Douleurs aigu\u00ebs","author":"Ferrell","year":"1996"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.011_bib0225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00003088-199936060-00005","article-title":"Glucuronidation in humans: pharmacogenetic and developmental aspects","volume":"36","author":"De Wildt","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.011_bib0230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0885-3924(02)00531-6","article-title":"Relationships among morphine metabolism, pain and side effects during long-term treatment: an update","volume":"25","author":"Andersen","year":"2003","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.011_bib0235","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/0269216311406577","article-title":"Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review","volume":"25","author":"Mercadante","year":"2011","journal-title":"Palliat Med"},{"issue":"10","key":"10.1016\/j.bulcan.2018.06.011_bib0240","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1200\/JCO.1998.16.10.3222","article-title":"Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain","volume":"16","author":"Bruera","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.011_bib0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-3959(97)00072-9","article-title":"Controlle-release oxycodone and morphine in cancer related pain","volume":"73","author":"Heiskanen","year":"1997","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.bulcan.2018.06.011_bib0250","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/sj.bjc.6601365","article-title":"Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients","volume":"89","author":"Lauretti","year":"2003","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.011_bib0255","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jjco\/hyn010","article-title":"Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial","volume":"38","author":"Narabayashi","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.011_bib0260","first-page":"56","article-title":"No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients","volume":"14","author":"Riley","year":"2006","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2018.06.011_bib0265","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jpainsymman.2012.02.025","article-title":"Opioid switching in patients with advanced cancer followed at home. A retrospective analysis","volume":"45","author":"Mercadante","year":"2013","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.011_bib0270","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0304-3959(95)00180-8","article-title":"Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain","volume":"64","author":"Donner","year":"1996","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.011_bib0275","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/0269216302pm536oa","article-title":"Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care","volume":"16","author":"McNamara","year":"2002","journal-title":"Palliat Med"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.011_bib0280","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jpainsymman.2007.12.024","article-title":"Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit","volume":"37","author":"Mercadante","year":"2009","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.011_bib0285","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ijc.11416","article-title":"Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl","volume":"107","author":"Mystakidou","year":"2003","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.011_bib0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1248\/yakushi.131.463","article-title":"Dose conversion in opioid rotation from continuous intravenous infusion of morphine hydrochloride injection to fentanyl patch in the management of cancer pain","volume":"131","author":"Kawano","year":"2011","journal-title":"Yakugaku Zasshi"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.011_bib0295","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jpainsymman.2004.12.010","article-title":"Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial","volume":"30","author":"Morita","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.bulcan.2018.06.011_bib0300","first-page":"1","article-title":"A randomized crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain","volume":"2","author":"Moriarty","year":"1999","journal-title":"J Drug Assess"},{"issue":"9","key":"10.1016\/j.bulcan.2018.06.011_bib0305","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ajp.0000210925.33783.4d","article-title":"Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial","volume":"22","author":"Wirz","year":"2006","journal-title":"Clin J Pain"},{"issue":"1\u20132","key":"10.1016\/j.bulcan.2018.06.011_bib0310","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0304-3959(97)00018-3","article-title":"Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study","volume":"72","author":"Lawlor","year":"1997","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.011_bib0315","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01.ftd.0000211827.03726.e4","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain","volume":"28","author":"Auret","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.011_bib0320","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jpainsymman.2008.05.016","article-title":"Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors","volume":"37","author":"Benitez-Rosario","year":"2009","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"10.1016\/j.bulcan.2018.06.011_bib0325","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.1996.14.10.2836","article-title":"Clinical experience with oral methadone administration in the treatment of pain in 196\u00a0advanced cancer patients","volume":"14","author":"De Conno","year":"1996","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2018.06.011_bib0330","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.1999.17.10.3307","article-title":"Rapid switching from morphine to methadone in cancer patients with poor response to morphine","volume":"17","author":"Mercadante","year":"1999","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2018.06.011_bib0335","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1200\/JCO.2001.19.11.2898","article-title":"Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study","volume":"19","author":"Mercadante","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.011_bib0340","first-page":"326","article-title":"Opioid plasma concentration during switching from morphine to methadone: preliminary data","volume":"11","author":"Mercadante","year":"2003","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.011_bib0345","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1017\/S1478951505050479","article-title":"Methadone in the treatment of pain and terminal delirum in advanced cancer patients","volume":"3","author":"Moryl","year":"2005","journal-title":"Palliat Support Care"},{"issue":"6266","key":"10.1016\/j.bulcan.2018.06.011_bib0350","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bmj.282.6266.771","article-title":"Patient-controlled dose regimen of methadone for chronic cancer pain","volume":"282","author":"S\u00e4we","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.011_bib0355","first-page":"26","article-title":"Methadone titration in opioid-resistant cancer pain","volume":"8","author":"Scholes","year":"1999","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"2","key":"10.1016\/j.bulcan.2018.06.011_bib0360","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1191\/0269216303pm696oa","article-title":"An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population","volume":"17","author":"Tse","year":"2003","journal-title":"Palliat Med"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.011_bib0365","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0885-3924(99)00083-4","article-title":"outpatient titration and monitoring strategies in cancer patients","volume":"18","author":"Hagen","year":"1999","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"10.1016\/j.bulcan.2018.06.011_bib0370","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1200\/JCO.1998.16.10.3216","article-title":"Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?","volume":"16","author":"Ripamonti","year":"1998","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.bulcan.2018.06.011_bib0375","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.ejca.2011.06.047","article-title":"How to switch from morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II trial","volume":"47","author":"Moksnes","year":"2011","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.011_bib0380","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3","article-title":"Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study","volume":"82","author":"Lawlor","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.011_bib0385","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0304-3959(01)00465-1","article-title":"Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain","volume":"96","author":"Moryl","year":"2002","journal-title":"Pain"},{"issue":"8","key":"10.1016\/j.bulcan.2018.06.011_bib0390","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1089\/jpm.2007.0285","article-title":"Switching from methadone to a different opioid: what is the equianalgesic dose ratio?","volume":"11","author":"Walker","year":"2008","journal-title":"J Palliat Med"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.011_bib0395","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.107.126052","article-title":"(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties","volume":"323","author":"Tzschentke","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.011_bib0400","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1185\/03007995.2013.791617","article-title":"Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids","volume":"29","author":"Mercadante","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.bulcan.2018.06.011_bib0405","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1185\/03007995.2014.934793","article-title":"Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain","volume":"30","author":"Mercadante","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.011_bib0410","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12325-013-0015-6","article-title":"Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study","volume":"30","author":"G\u00e1lvez","year":"2013","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.011_bib0415","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/clpt.1990.85","article-title":"Morphine and oxycodone hydrochloride in the management of cancer pain","volume":"47","author":"Kalso","year":"1990","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.011_bib0420","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0885-3924(96)00329-6","article-title":"A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain","volume":"13","author":"Nelson","year":"1997","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.011_bib0425","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0269216309346595","article-title":"The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain","volume":"24","author":"Lasheen","year":"2010","journal-title":"Palliat Med"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.011_bib0215","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jpainsymman.2016.05.022","article-title":"Efficacy and safety of two methadone titration methods for the treatment of cancer-related pain: The EQUIMETH2\u00a0trial (methadone for cancer-related pain)","volume":"52","author":"Poulain","year":"2016","journal-title":"J Pain Symptom Manage"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511830225X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511830225X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:30:24Z","timestamp":1757791824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745511830225X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S000745511830225X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.06.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La morphine dans le cadre du changement d\u2019opio\u00efdes ou de voie d\u2019administration, chez l\u2019adulte avec une douleur due au cancer","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}